Physician profile
Julie Stackhouse
NPI 1447275268
$3,722.92
in general payments reported to CMS, 2019-2025
22 companies · $1,170 in 2025
The $1,170 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $443 · 2022: $512 · 2023: $842 · 2024: $756 · 2025: $1,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electronic Waveform Lab, INC. | $805.46 | 2021-2025 | |
| Boston Scientific Corporation | $720.68 | 2021-2025 | Intracept, Infinion 16, General - Pain Management |
| Medtronic, INC. | $394.47 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $351.62 | 2021-2025 | Relistor |
| Painteq LLC | $233.27 | 2024 | Painteq |
| Saluda Medical Americas, INC. | $187.21 | 2024 | Evoke |
| Relievant Medsystems, INC. | $181.04 | 2022-2023 | Intracept |
| Collegium Pharmaceutical, INC. | $149.14 | 2021-2024 | Belbuca |
| Si-Bone, INC. | $122.20 | 2023-2025 | |
| Scilex Pharmaceuticals INC. | $114.18 | 2021-2024 | Ztlido |
| Almatica Pharma LLC | $107.84 | 2022-2023 | Gralise |
| Biodelivery Sciences International, INC. | $51.86 | 2021 | |
| Spr Therapeutics, INC | $45.05 | 2023-2025 | Sprint Pns System |
| Biohaven Pharmaceutical Holding Company LTD. | $44.31 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $42.80 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $38.64 | 2022-2023 | |
| Abbott Laboratories | $34.17 | 2022-2023 | Proclaim |
| Nalu Medical, INC. | $27.73 | 2025 | Nalu Neurostimulation System |
| Amgen INC. | $21.49 | 2025 | Krystexxa |
| Azurity Pharmaceuticals, INC. | $19.82 | 2024 | Horizant |
| Averitas Pharma INC. | $15.00 | 2023 | Qutenza |
| Nevro Corp. | $14.94 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Stackhouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.